What is our technology?
Erimos Pharmaceuticals is focused on the discovery and development of small molecule therapeutics to treat cancer and viral diseases. Erimos’ technology platform is directed at Sp1-regulated genes and proteins over-expressed in cancer (e.g. survivin) or required for viral replication. Terameprocol, our lead product in development, is drawn from a class of compounds preventing tumor cell replication and promoting selective tumor cell death, or apoptosis. The drug is designed specifically to target abnormal tumor cells while causing little or no toxicity to healthy cells. Terameprocol also shows anti-viral effects against human immunodeficiency virus (HIV), herpes simplex virus (HSV), and human papillomavirus (HPV) and reduces cell proliferation and certain harmful cellular responses to viral infection.
Terameprocol is the semi-synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA). Erimos has developed a novel process to extract NDGA from the resin of the leaves of Larrea tridentata, a desert bush indigenous to the southwestern US and Mexico. The chemical structure of Terameprocol was designed to make it pharmacologically distinct from NDGA. Erimos’ technology platform includes additional proprietary molecules in early stage development.
Where is Terameprocol in its development?
Erimos primary clinical focus has been the evaluation of terameprocol administered intravenously to patients with various forms of cancer. Four Phase I clinical studies have been conducted. These trials have accessed: two different treatment schedules in patients with refractory solid tumors; patients with refractory leukemias, and patients with refractory gliomas. Results from these trials have been encouraging and Phase II studies are being planned.
Earlier clinical studies evaluated terameprocol administered intravaginally to patients with cervical intraepithelial neoplasia (CIN) and using localized injection in patients with head and neck cancers. Encouraging results were reported from these trials.
Oral formulation has been developed for terameprocol by Erimos to improve patient experience and enhance efficacy. Clinical study of oral administration is on going for glioma and plans are in place for other indications.